Literature DB >> 7161556

Transfer of human lymph chylomicron constituents to other lipoprotein density fractions during in vitro lipolysis.

E J Schaefer, M G Wetzel, G Bengtsson, R O Scow, H B Brewer, T Olivecrona.   

Abstract

To ascertain whether chylomicron constituents would be transferred to low density lipoprotein (LDL, d 1.019-1.063 g/ml) and high density lipoprotein (HDL, d 1.063-1.21 g/ml) density fractions during lipolysis in the absence of other lipoproteins, the in vitro effect of bovine milk lipoprotein lipase on human thoracic duct lymph chylomicrons in the presence of albumin was examined. In incubations without lipase, over 90% of chylomicron constituents remained in the 1.006 g/ml supernate, and large particles ranging in diameter mainly from 750-6000 A were observed by electron microscopy. After the addition of lipase, lipolysis ranged from 69.0-94.6% and numerous collapsed particles with redundant surface were seen, as well as smaller particles within the LDL and HDL density region. With lipolysis, the majority of chylomicron cholesterol and phospholipid mass was transferred to LDL and HDL, while chylomicron apolipoprotein (apo) A-I, A-II, and C-II mass was transferred mainly to HDL. Utilizing either radioiodinated apoA-I and apoA-II reassociated with chylomicrons or radiolabeled chylomicrons, a similar redistribution of apoA-I and apoA-II radioactivity was noted with lipolysis. In contrast, chylomicron apoB (mainly B-48) radioactivity was transferred predominantly to LDL with lipolysis. These data are consistent with the concept that during lymph chylomicron triglyceride hydrolysis, chylomicron apolipoproteins, cholesterol, and phospholipid can be transferred to the LDL and HDL density regions in the absence of acceptor particles.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7161556

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  8 in total

1.  Postprandial remodeling of high-density lipoprotein following high saturated fat and high carbohydrate meals.

Authors:  Michelle Averill; Katya B Rubinow; Kevin Cain; Jake Wimberger; Ilona Babenko; Jessica O Becker; Karen E Foster-Schubert; David E Cummings; Andrew N Hoofnagle; Tomas Vaisar
Journal:  J Clin Lipidol       Date:  2019-11-22       Impact factor: 4.766

2.  Association between sympathetic activity and the atherogenic serum cholesterol fraction.

Authors:  P Weidmann; D C Schohn; W Riesen; H A Jahn; P Ferrari; S G Shaw; C Beretta-Piccoli
Journal:  Klin Wochenschr       Date:  1990-03-05

3.  The Lipid Energy Model: Reimagining Lipoprotein Function in the Context of Carbohydrate-Restricted Diets.

Authors:  Nicholas G Norwitz; Adrian Soto-Mota; Bob Kaplan; David S Ludwig; Matthew Budoff; Anatol Kontush; David Feldman
Journal:  Metabolites       Date:  2022-05-20

4.  Hepatic overexpression of bovine scavenger receptor type I in transgenic mice prevents diet-induced hyperbetalipoproteinemia.

Authors:  S Wölle; D P Via; L Chan; J A Cornicelli; C L Bisgaier
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

6.  The effect of insulin deficiency on the plasma clearance and exchange of high-density-lipoprotein phosphatidylcholine in rats.

Authors:  I J Martins; T G Redgrave
Journal:  Biochem J       Date:  1992-02-01       Impact factor: 3.857

Review 7.  Lipoprotein metabolism. An overview.

Authors:  J Shepherd
Journal:  Drugs       Date:  1994       Impact factor: 9.546

8.  Effect of fasting and feeding on apolipoprotein A-I kinetics in preβ1-HDL, α-HDL, and triglyceride-rich lipoproteins.

Authors:  Maud Chétiveaux; Mikaël Croyal; Khadija Ouguerram; Fanta Fall; Laurent Flet; Yassine Zair; Estelle Nobecourt; Michel Krempf
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.